Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAMBA: HepB mAb19 in Chronic Hepatitis B
NCT06668727Phase 1Recruiting
- Sponsor
- Aarhus University Hospital
- Start
- Aug 2024
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HepB mAb19 in Chronic Hepatitis B (CHB) (4 arms), sponsored by Aarhus University Hospital. Primary endpoints: Safety and tolerability at 48 weeks, Pharmacokinetic profile at 48 weeks and 1 more. Started Aug 2024; status: recruiting.
02
Drugs
HepB mAb19
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06668727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06668727.